Insmed discontinues development of its drug candidate brensocatib for hidradenitis suppurativa after a mid-stage clinical trial failed to meet its pri...
Baker Hostetler attorney Winston Kirton says life sciences companies that are active in both the U.S. and the EU need to change their view of supply c...
A Clinical Trial Vanguard online column explains how a 2022 FDA master protocol guidance has not kept pace with non-oncology basket trial developments...
FDA removes partial clinical hold against MacroGenics Phase 2 LINNET study evaluating the investigational cancer therapy lorigerlimab.
An FDA Matters column calls on FDA to fully enforce the laws against mass compounding of approved drugs that are not in shortage.
FDA warns Glens Falls, NY-based Medline Industries about Quality System violations in its manufacturing and assembly of cardiovascular procedure kits.
FDA solicits applications for its new READI-Home innovation challenge to use medical technology in the home to reduce or prevent hospital readmissions...
Healthcare advocacy organizations call on key House lawmakers to hold hearings and advance bipartisan legislation aimed at lowering prescription drug ...
